Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 5/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15774380 | 0.87 | RXRA (0.51) | DHFRMAOBCYP1A2CYP2D6CYP19A1 | |
| SCHEMBL17201438 | 0.84 | MAOB (0.56) | MAOBCYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL15774756 | 0.83 | CYP1A2 (0.56) | DHFRMAOBCYP1A2CYP2D6CYP19A1 | |
| SCHEMBL15774727 | 0.82 | MAOB (0.60) | MAOBCYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL17201421 | 0.80 | CYP1A2 (0.52) | MAOBCYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL17201431 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL17201436 | 0.77 | CYP1A2 (0.56) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL15774638 | 0.77 | RXRA (0.62) | DHFRMAOBRXRARXRBRXRG | |
| SCHEMBL15774615 | 0.76 | RXRA (0.54) | DHFRMAOBCYP1A2CYP2C19RXRA | |
| SCHEMBL17201437 | 0.76 | CYP1A2 (0.54) | MAOBCYP1A2CYP2D6CYP19A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296711-B2 | Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1) | HOFFMAN-LA ROCHE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150307463-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | HOFFMANN-LA ROCHE INC. | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307463-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | SCD, SCD5, CPT1A | DHFR 356/4885MAOB 3277/4885CYP1A2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.